Colin McKay, DPM
Foot & Ankle Surgery · Richland, WANPI 1417486606
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,768 of the $8,841 with a category attached, or 87.9%. ALON Medical Technology accounts for 88.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $7,798 and has fallen 97.6% since, to $187 in 2025.
Across 36 payments — averaging $245.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ALON Medical Technology$8K
- Stryker$601
- Biowound Solutions, Inc.$104
- Integra Lifesciences Corporation$100
- Organogenesis Inc.$99
- Mimedx Group, Inc.$47
- plus $93 from 4 others
What the payments were for
- Travel & lodging$3023%
- Food & beverage$7719%
- Education$7,76888%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ALON Medical Technology | 12 | $7,798 |
| Stryker | 8 | $601 |
| Biowound Solutions, Inc. | 4 | $104 |
| Integra Lifesciences Corporation | 1 | $100 |
| Organogenesis Inc. | 4 | $99 |
| Mimedx Group, Inc. | 2 | $47 |
| Smith+Nephew | 2 | $32 |
| Next Science LLC | 1 | $26 |
| Bioventus LLC | 1 | $19 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NA$302
- AUGMENT INJECTABLE$138
- TENOGLIDE$100
How this compares
$8,841 in reported general payments places this provider in the 80th percentile of 203 foot & ankle surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 31 | $640 |
| Gabapentin | 60 | $575 |
| Linezolid | 12 | $502 |
| Ciclopirox | 12 | $298 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 36 | $276 |
| Methylprednisolone | 27 | $260 |
| Fluconazole | 16 | $226 |
| Cephalexin | 26 | $150 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $125 |
| Doxycycline Hyclate | 11 | $57 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Richland
- Jeffrey ChristensenEverett$828K
- David DalstromSeattle$491K
- Richard LamourOlympia$87K
- Adam AlbabaSeattle$46K
- Stephen BenirschkeSeattle$45K
- Craig CliffordFederal Way$44K
- Shawn KhademiRenton$43K
- Gregory GrabowskiBellevue$34K
- Jacob McLeodLongview$34K
- Garrett PereskoMorton$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.